How often are hormone injections given for prostate cancer?
LHRH agonists are injected or placed as small implants under the skin. Depending on the drug used, they are given anywhere from once a month up to once every 6 months.
How long can you stay on Lupron for prostate cancer?
Lupron controls prostate cancer for an average duration of 18 to 24 months in men with metastatic disease. When Lupron stops working, other hormonal agents such as Casodex or Nilandron may provide temporary control, but their duration of effect (keeping the PSA down) usually lasts for less than a year.
What are the side effects of Lupron for prostate cancer?
Other potential side effects of Lupron can include:
- skin reaction at the injection site.
- shrunken testicles.
- hot flashes.
- mood swings.
- breast tenderness or growth of breast tissue.
- erectile dysfunction or loss of sex drive.
- loss of muscle mass.
How long can you live on hormone therapy?
On average, hormone therapy can stop the advance of cancer for two to three years. However, it varies from case to case. Some men do well on hormone therapy for much longer.
Can you live 10 years with metastatic prostate cancer?
Of the 794 evaluable patients, 77% lived < 5 years, 16% lived 5 up to 10 years, and 7% lived > or = 10 years. Factors predicting a statistical significant association with longer survival (P < 0.05) included minimal disease, better PS, no bone pain, lower Gleason score, and lower PSA level.
Can you live 20 years with prostate cancer?
Men with Gleason 7 and 8 to 10 tumors were found to be at high risk of dying from prostate cancer. After 20 years, only 3 of 217 patients survived. Men with moderate-grade disease have intermediate cumulative risk of prostate cancer progression after 20 years of follow-up.
What is the most aggressive prostate cancer?
Small cell carcinoma, the most aggressive type of neuroendocrine cancer in the prostate that develops in small round cells of the neuroendocrine system.
How long can a man stay on hormone therapy for prostate cancer?
Hormone therapy can help shrink the prostate and any cancer that has spread, and make the treatment more effective. You may be offered hormone therapy for up to six months before radiotherapy. And you may continue to have hormone therapy during and after your radiotherapy, for up to three years.
What happens when you stop taking Lupron for prostate cancer?
If Lupron treatment is stopped, testosterone levels can rise and your cancer may worsen. Do not discontinue Lupron Depot unless your doctor tells you to stop treatment. In men, testosterone is reduced to castrate concentrations with Lupron Depot treatment.
How does Lupron make you feel?
Mild burning/pain/bruising at the injection site, hot flashes (flushing), increased sweating, night sweats, tiredness, headache, upset stomach, breast changes, acne, joint/muscle aches, trouble sleeping, reduced sexual interest, vaginal discomfort/dryness, vaginal bleeding, swelling of the ankles/feet, increased …
Does prostate removal affect testosterone levels?
The serum level of testosterone (Te) may affect sexual function in males treated by radical prostatectomy (RP) for clinically localized prostate cancer (PCa) (3).
What does hormone therapy do to a man?
Hormone therapy lowers the amount of testosterone in the body and this affects your ability to have and maintain an erection. This may get better within 3 to 12 months after the treatment ends. For some men, erection problems are permanent. It depends on the drug you are having and how long you have been taking it.
What is the success rate of hormone therapy?
The 6-year survival rate for HRT users was 92% compared with 80% for nonusers (P = . 05) (Figure 2). Figure 3 shows survival curves for patients with tumors detected by palpation. The 6-year survival rate was 79% for HRT users compared with 76% for nonusers (P = .
Do you need hormone replacement after prostate removal?
It found that men with low PSA levels after prostate surgery gained no overall survival benefit from long-term hormone therapy. Even worse, the authors report, the risk of dying from other causes was substantially increased in those patients.